What Is Trulicity?

1. The Short Answer

Trulicity is an injectable prescription medicine whose active ingredient is dulaglutide. The current DailyMed label identifies Trulicity as a GLP-1 receptor agonist and lists the label as revised in March 2026.

The main U.S. label context is type 2 diabetes. DailyMed describes Trulicity as used with diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The same label also includes a cardiovascular-risk reduction indication for adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

The official Trulicity site says the same thing in consumer-facing language: Trulicity is for adults and children 10 years and older with type 2 diabetes to improve blood sugar, and it is also used in adults with type 2 diabetes to reduce risk of major cardiovascular events in people with heart disease or multiple cardiovascular risk factors.

That is narrower than much of the public GLP-1 conversation. Trulicity is not a general nickname for weight-loss drugs, semaglutide products, or tirzepatide products. It is a dulaglutide brand with its own label.

2. What Is Dulaglutide?

Dulaglutide is the active ingredient in Trulicity. In plain language, dulaglutide belongs to the GLP-1 receptor agonist group, a medicine category designed around glucagon-like peptide-1 receptor signaling. For class background, see What Is a GLP-1?.

GLP-1 receptor agonist is a class description, not a brand name. NCBI Bookshelf’s GLP-1 receptor agonist comparison places dulaglutide and semaglutide in the GLP-1 receptor agonist family and separately describes tirzepatide as a dual GIP/GLP-1 receptor agonist. That distinction is the simplest way to understand why Trulicity, Ozempic, and Mounjaro are related in conversation but not identical.

The brand-versus-molecule split matters:

That vocabulary does not answer treatment questions. It simply keeps the names from collapsing into one vague category.

3. Why Is Trulicity Part of the GLP-1 Conversation?

Trulicity is part of the GLP-1 conversation because dulaglutide is a GLP-1 receptor agonist. Lilly announced FDA approval of Trulicity in 2014 as a once-weekly therapy for adults with type 2 diabetes, years before the more recent public attention around Ozempic, Wegovy, Mounjaro, and Zepbound.

The category has expanded since then. Public use of “GLP-1” now often covers several different ideas at once: the natural hormone, the receptor, GLP-1 receptor agonist medicines, dual incretin medicines, diabetes brands, weight-management brands, and online discussion about appetite and body weight. That shorthand can be useful, but it can also hide important differences.

Trulicity’s place in the conversation is more specific. It is a dulaglutide product, not a semaglutide product. It is a GLP-1 receptor agonist, not a dual GIP/GLP-1 receptor agonist. Its U.S. label sits in type 2 diabetes and defined cardiovascular-risk reduction for adults with type 2 diabetes, not in a general weight-management label.

For related molecule explainers, see What Is Semaglutide? and What Is Tirzepatide?.

4. Trulicity vs Ozempic and Wegovy

Trulicity, Ozempic, and Wegovy all appear in GLP-1 searches, but the names point to different products. The cleanest first distinction is the active ingredient: Trulicity contains dulaglutide, while Ozempic and Wegovy contain semaglutide.

The Ozempic DailyMed label describes Ozempic as semaglutide. Ozempic’s U.S. label is centered on type 2 diabetes, with additional defined cardiovascular and kidney-related indications in adult type 2 diabetes populations. For a separate page on that brand context, see What Is Ozempic?.

Wegovy is also semaglutide, but the Wegovy DailyMed label has a different brand context, including chronic weight management and other defined labeled uses. That does not make Wegovy a casual substitute for Ozempic or Trulicity; it means one molecule can sit under more than one brand label.

The high-level map looks like this:

This is a naming and label comparison only. It does not rank products or suggest that any product is right for a particular person.

5. Trulicity vs Mounjaro and Zepbound

Trulicity and Mounjaro are both Lilly brands discussed in type 2 diabetes and incretin-drug conversations, but they contain different active ingredients. Trulicity contains dulaglutide. Mounjaro contains tirzepatide.

That difference changes the receptor language. Trulicity’s label describes dulaglutide as a GLP-1 receptor agonist. The Mounjaro DailyMed label describes tirzepatide as a GIP and GLP-1 receptor agonist. For a separate explanation, see What Is Mounjaro?.

Zepbound adds another layer because it also contains tirzepatide in the United States, but it has a different brand label from Mounjaro. The Zepbound DailyMed label is not the Trulicity label and not the Mounjaro label, even though Mounjaro and Zepbound share the tirzepatide active ingredient.

One useful way to avoid confusion is to separate three fields before comparing anything:

• Brand: Trulicity, Mounjaro, or Zepbound.
• Active ingredient: Dulaglutide or tirzepatide.
• Receptor description: GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.

Those fields are factual. They are useful for keeping Trulicity, Mounjaro, and Zepbound separate, not for choosing between them.

6. What About Cardiovascular-Risk Reduction?

Cardiovascular-risk reduction belongs in a Trulicity explainer because it is in the current U.S. label. DailyMed states that Trulicity is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Lilly announced the FDA cardiovascular-risk reduction approval in February 2020, describing it as an expansion of Trulicity’s label. The current label remains the stronger source for what the U.S. indication says now, but the approval history helps explain why older articles may discuss Trulicity as more than a blood-sugar-only brand.

The important boundary is population and wording. The cardiovascular language is tied to adults with type 2 diabetes in defined risk groups. It is not a broad claim that Trulicity prevents heart problems for everyone, and it is not advice to choose Trulicity for cardiovascular reasons.

7. Why Trulicity Search Results Get Messy

Trulicity searches get messy because people often start with a brand name and then ask class, molecule, label, and comparison questions at the same time. “Is Trulicity a GLP-1?” is a class question. “Is Trulicity the same as Ozempic?” is an active-ingredient and brand question. “Is Trulicity for weight loss?” is a label-context question. “Should I switch?” is a medical decision question.

Only some of those are suitable for a general explainer. This page can answer the first three at a high level: Trulicity is a GLP-1 receptor agonist brand; it contains dulaglutide; it is different from semaglutide and tirzepatide products; and its U.S. label is centered on type 2 diabetes with defined cardiovascular-risk reduction context.

A personal switch question is different because it depends on facts this page does not have: the person’s current product, label context, health history, side effects, goals, and clinician guidance.

If the task is recordkeeping rather than medical decision-making, it helps to log the plain facts separately: brand, active ingredient, route, label source, date, and notes from the prescribing clinician. That is different from using a website to make a medication choice.

8. Sources

9. Trulicity FAQ

• What is Trulicity in simple terms?

  Trulicity is the Lilly brand name for dulaglutide injection. The current U.S. label describes it as a once-weekly GLP-1 receptor agonist used with diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes mellitus.

• Is Trulicity the same thing as dulaglutide?

  No. Dulaglutide is the active ingredient, while Trulicity is the brand name. The distinction matters because brand names, active ingredients, labels, and patient instructions are not the same kind of information.

• How is Trulicity different from Ozempic?

  Trulicity contains dulaglutide and Ozempic contains semaglutide. Both are GLP-1 receptor agonist products associated with type 2 diabetes, but they are different active ingredients with separate U.S. labels.

• How is Trulicity different from Mounjaro?

  Trulicity contains dulaglutide and is described as a GLP-1 receptor agonist. Mounjaro contains tirzepatide and is described as a GIP and GLP-1 receptor agonist. They are different molecules and different brand labels.